Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

12.520
+0.1301.05%
Volume:2.84M
Turnover:35.74M
Market Cap:12.42B
PE:-37.32
High:12.780
Open:12.390
Low:12.030
Close:12.390
52wk High:18.750
52wk Low:2.820
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:1.06
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.335
ROE:-12.77%
ROA:-12.32%
PB:5.95
PE(LYR):-37.32
PS:4705.00

Loading ...

ASCLETIS-B (01672): Positive Topline Results from 13-Week Phase II Study of ASC30 for Obesity Treatment

Stock News
·
Dec 08, 2025

Ascletis Pharma Reports 7.7% Placebo-Adjusted Weight Loss With Oral GLP-1 Drug ASC30 in Phase II Obesity Study

Reuters
·
Dec 08, 2025

ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted

Stock News
·
Dec 08, 2025

Is Ascletis Pharma (SEHK:1672) Quietly Reframing Its Obesity Strategy With ASC37’s Oral Triple Agonist?

Simply Wall St.
·
Dec 07, 2025

Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing

Simply Wall St.
·
Dec 05, 2025

ASCLETIS-B (01672) Repurchases 1.62 Million Shares for HK$20.94 Million on December 4

Stock News
·
Dec 04, 2025

Ascletis Pharma Files HKEX Disclosure on Repurchase of 1.62 Million Shares for HK$20.94 Million

Reuters
·
Dec 04, 2025

HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%

Tiger Newspress
·
Dec 04, 2025

Hong Kong Stock Buyback Summary | December 4

Stock News
·
Dec 04, 2025

ASCLETIS-B (01672) Repurchased 1.306 Million Shares for HK$15.9275 Million on December 3

Stock News
·
Dec 03, 2025

Ascletis Pharma Repurchases 1,306,000 Shares for HKD 15.93 Million in HKEX Filing

Reuters
·
Dec 03, 2025

HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.

Tiger Newspress
·
Dec 03, 2025

Zhixiang HK Morning Brief | NY Silver Futures Surge Over 6% Last Friday; MIIT to Regulate Irrational Competition in Power and Energy Storage Battery Industry

Stock News
·
Dec 01, 2025

ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development

Stock News
·
Nov 30, 2025

Ascletis Pharma Expects to Submit Investigational New Drug Application to U.S. FDA for Asc37 Oral Tablets in Second Quarter of 2026

THOMSON REUTERS
·
Nov 30, 2025

BRIEF-Ascletis To Submit IND To U.S. FDA For ASC37 Oral Tablets In 2nd Qtr Of 2026

Reuters
·
Nov 30, 2025

Ascletis Unveils Potent Oral Triple Agonist ASC37 for Obesity Treatment

Reuters
·
Nov 30, 2025

HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%

Tiger Newspress
·
Nov 26, 2025

Will Promising Preclinical Results in Obesity Candidates Reshape Ascletis Pharma's (SEHK:1672) Innovation Narrative?

Simply Wall St.
·
Nov 25, 2025

HK Stock Movement | ASCLETIS-B (01672) Rises Over 6% as Pharma Firms Actively Develop Ultra-Long-Acting Therapies; Company Boasts ULAP Technology Platform

Stock News
·
Nov 25, 2025